Evaluation of a new commercial real-time PCR assay for diagnosis of Pneumocystis jirovecii pneumonia and identification of dihydropteroate synthase (DHPS) mutations

详细信息    查看全文

• 作者：Isabel Montesinos^a ; ^{Carlota.Montesinos@erasme.ulb.ac.be} ; ^{carlotamontesinos@terra.com} ; Marie-Luce Delforge^a ; ^{Marie-Luce.Delforge@erasme.ulb.ac.be} ; Farida Ajjaham^a ; ^{Farida.Ajjaham@erasme.ulb.ac.be} ; Franç ; oise Brancart^a ; ^{francoise.brancart@uclouvain.be} ; Maya Hites^b ; ^{Maya.Hites@erasme.ulb.ac.be} ; Frederique Jacobs^b ; ^{Frederique.Jacobs@erasme.ulb.ac.be} ; Olivier Denis^a ; ^{odenis@ulb.ac.be}
• 关键词：Pneumocystis jirovecii pneumonia ; Commercial real-time PCR ; DHPS mutations ; Trimethoprim-sulfamethoxazole resistance
• 刊名：Diagnostic Microbiology and Infectious Disease
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：87
• 期：1
• 页码：32-36
• 全文大小：489 K
• 卷排序：87

文摘

We have evaluated the performances of PneumoGenius real-time PCR that combines Pneumocystis amplification and the detection of DHPS mutations. PneumoGenius real-time PCR has shown comparable performances to an ‘in house’ real-time PCR and another commercial quantitative real-time PCR assay, the Bio-Evolution Pneumocystis jirovecii real-time PCR, in discriminating Pneumocystis pneumonia and colonization. A 100% agreement was obtained between PneumoGenius® PCR and the “in house” PCR and sequencing method for DHPS mutation identification We observed a low rate of P. jirovecii harboring DHPS mutations (4.5%) in our hospital population.